An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.

Trial Profile

An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2015

At a glance

  • Drugs ABT 072; Paritaprevir; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms Pilot
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 20 Apr 2012 Primary endpoint 'Virological-response-rate' has been met.
    • 04 Apr 2012 Results will be presented at the 47th Annual Meeting of the European Association for the Study of the Liver, according to an Enanta Pharmaceuticals media release.
    • 01 Apr 2012 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top